Metastatic Esophageal Cancer: What to Ask

Half of it happens at the first appointment. NCI reports a stark figure. About 50% of patients with esophageal cancer already have metastatic disease when diagnosed. Those patients are candidates for palliative therapy.

That is not a reason for despair. It does explain the pace, though. The conversation turns quickly to symptom control alongside cancer treatment. Both usually start at once.

NCI's treatment lists split by histology, so this is the fork in the road.

Squamous cell carcinoma comes from the flat lining cells. Adenocarcinoma comes from gland cells. It is grouped with cancer of the gastroesophageal junction, where the esophagus meets the stomach.

The difference is not cosmetic. NCI lists separate options for each type. The trials behind them enrolled different patients. So ask two things. Which type does the pathology report name? And where in the esophagus does the tumor sit?

NCI's summary states the current position directly. First-line chemoimmunotherapy can now be considered the standard of care. That applies to advanced esophageal cancer of either type, with PD-L1 expression. NCI adds one caveat in the same sentence. The best cutoff still needs to be defined.

That caveat is why the CPS number is worth asking about by name.

KEYNOTE-590 is the trial to know. It screened 1,020 patients with untreated esophageal cancer. The disease had to be locally advanced, unresectable, or metastatic. Siewert type 1 junction cancers were included. PD-L1 status did not affect entry. It then randomized 749 patients to pembrolizumab or placebo. Both arms got 5-FU on days 1 through 5, and cisplatin on day 1, for up to 6 cycles, at amounts the treating team works out from body size. Treatment repeated every 3 weeks, for up to 35 cycles.

Median overall survival, pembrolizumab versus placebo:

• Squamous cell carcinoma with CPS of 10 or more: 13.9 months versus 8.8 months.
• Squamous cell carcinoma overall: 12.6 months versus 9.8 months.
• Any histology with CPS of 10 or more: 13.5 months versus 9.4 months.
• All randomized patients: 12.4 months versus 9.8 months.

At 24 months, survival roughly doubled in each of those groups, at about 30% versus 15%.

Now the number that cuts the other way. It is the one to bring up. An exploratory analysis looked at patients with a CPS below 10. Median overall survival was 10.5 months with pembrolizumab and 10.6 months without. Serious treatment-related side effects ran 72% with pembrolizumab and 68% with placebo.

So a low CPS is a legitimate reason to ask what immunotherapy is expected to add.

HER2 is worth asking about. NCI's summary covers chemotherapy given with anti-HER2 therapy. One such regimen is fluorouracil, leucovorin, oxaliplatin, and docetaxel, plus trastuzumab and pertuzumab.

Two other markers are worth naming, for a different reason. NCI's esophageal summary does not address claudin 18.2 testing. It also does not address mismatch repair or microsatellite instability testing. If either comes up, ask what evidence it rests on. Ask whether it applies to this cell type. It is not coming from this summary.

This is often the symptom that matters most day to day, and NCI is specific about it.

NCI names one method as recommended for relieving dysphagia. That is placement of a self-expandable metal stent. A stent is a mesh tube put in by endoscopy. It holds the esophagus open.

Other listed options:

• Radiation therapy, with or without intraluminal intubation and dilation.
• Intraluminal brachytherapy, meaning radiation delivered from inside the esophagus.
• Nd:YAG laser destruction of tumor inside the channel.
• Electrocoagulation.

One question is worth asking about timing. Should one of these happen now, rather than waiting for chemotherapy to work?

NCI also notes what happens with complete blockage. When the esophagus is fully blocked and there is no sign of spread through the body, the traditional fix has been surgery. The tumor is removed and the stomach is moved up to replace the esophagus.

NCI's options for stage IV disease include several that are easy to miss:

• Chemoradiation followed by surgery, for stage IVA disease specifically.
• Chemotherapy, which has produced partial responses in metastatic distal esophageal adenocarcinoma.
• Adjuvant therapy after complete resection with negative margins, when residual disease remained after chemoradiation.
• Immunotherapy after relapse following one prior line of standard therapy.
• Nivolumab with chemotherapy for adenocarcinoma.
• Clinical trials of single-agent or combination chemotherapy.

Note the first line on that list. Stage IVA is treated differently from the rest of stage IV. So it is worth confirming which one applies.

For cancer that comes back after treatment, NCI lists a shorter set. It covers palliative use of any of the other therapies, including supportive care, plus immunotherapy and chemoimmunotherapy for recurrent squamous cell carcinoma.

NCI is blunt. The survival rate for esophageal cancer is poor. Surgery for removable disease gives 5-year survival of 5% to 30%. The better numbers come from earlier stages.

It also explains why the stage tends to be advanced at diagnosis. Small tumors stay inside the mucosa or submucosa. They cause no symptoms and are found by chance. By the time swallowing gets hard, the cancer has usually reached the muscularis propria or beyond. It may have spread to lymph nodes or other organs.

That sequence is why symptom questions and treatment questions arrive together here, rather than one after the other.

Our page on esophageal cancer covers the earlier stages, and our page on palliative care explains how symptom-focused care runs alongside treatment.

• Call 911 or go to an emergency department if you cannot swallow your own saliva, or food is stuck and will not go down or come back up. Go too if you vomit blood, or pass black tarry stools, and go for sudden severe chest pain or breathlessness. Go also for a temperature of 100.4°F (38°C) or higher, or shaking chills, when you are on chemotherapy or chemoimmunotherapy. The 5-FU and cisplatin behind these regimens flatten your white cells between cycles, and CDC ranks that fever as a medical emergency. Be seen now instead of leaving a message.
• Call your care team the same day if you cough or choke every time you drink, which can mean a connection has opened between the food pipe and the airway. Call the same day for a day of not keeping fluids down, and, if you are on immunotherapy, for a new cough or breathlessness or for diarrhea several times more often than usual.
• Call your care team within a day or two if swallowing is steadily getting harder, or feels narrow again after a stent was placed. Do the same for new hoarseness, for pain behind the breastbone when you swallow, and for weight dropping because you cannot get enough in.

• National Cancer Institute, Esophageal Cancer Treatment (PDQ) - Health Professional Version, accessed August 6, 2026
• National Cancer Institute, Esophageal Cancer Treatment (PDQ) - Patient Version, accessed August 6, 2026
• National Cancer Institute, Infection and Neutropenia During Cancer Treatment, accessed August 11, 2026
• National Cancer Institute, Immune Checkpoint Inhibitors, accessed August 11, 2026
• CDC, Watch Out for Fever (Preventing Infections in Cancer Patients), accessed August 13, 2026